4-(4-溴苯氧基)-哌啶盐酸盐 | 63843-58-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(4-溴苯氧基)-哌啶盐酸盐
• 中文别名: 4-(4-溴苯氧基)哌啶盐酸盐
• 英文名称: 4-(4-bromophenoxy)piperidine hydrochloride
• 英文别名: 4-(4-bromophenoxy)piperidine;hydrochloride
• CAS: 63843-58-3
• 化学式: C₁₁H₁₄BrNO*ClH
• 分子量: 292.603
• InChiKey: IOPDEOBAKDCJMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.0
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-(2-溴乙基)吲哚 、 4-(4-溴苯氧基)-哌啶盐酸盐 在 potassium carbonate 作用下， 以 异丙醇 为溶剂， 生成 3-{2-[4-(4-bromo-phenoxy)-piperidin-1-yl]-ethyl}-indole
  参考文献：
  名称：

  Method of treating pain and hypertension

  摘要：

  描述了具有降压、镇痛和镇静特性的3-[2-(苯氧环氮烷基)乙基]吲哚化合物及其制备方法。

  公开号：

  US04031221A1
• 作为产物：
  描述：

  对溴氟苯 生成 4-(4-溴苯氧基)-哌啶盐酸盐
  参考文献：
  名称：

  Method of treating pain and hypertension

  摘要：

  描述了具有降压、镇痛和镇静特性的3-[2-(苯氧环氮烷基)乙基]吲哚化合物及其制备方法。

  公开号：

  US04031221A1

文献信息

• [EN] INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] COMPOSÉS INDAZOLE UTILISÉS COMME INHIBITEURS DE KINASE ET MÉTHODE DE TRAITEMENT DU CANCER AVEC LESDITS COMPOSÉS
  申请人：UNIV HEALTH NETWORK

  公开号：WO2013053051A1

  公开（公告）日：2013-04-18

  The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

  本教学提供了由结构式（I）或（I'）表示的吲唑化合物或其药用可接受的盐。还描述了这些药物组合物及其用作蛋白激酶抑制剂的方法，如对乳腺癌细胞、结肠癌细胞和卵巢癌细胞具有抗癌活性的TTK蛋白激酶、极化样激酶4（PLK4）和极化激酶。
• Six membered heteroaromatic inhibitors targeting resistant kinase mutations
  申请人：Noronha Glenn

  公开号：US20070149508A1

  公开（公告）日：2007-06-28

  A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.

  提供了一种化合物，其一般结构为(A)：其中A是(未)取代芳基或(未)取代杂环芳基基团，G是N、CH或CR，R是未取代或取代的较低烷基，Y是疏水连接基团，L是定义的取代基。化合物(A)可用于治疗各种与血管生成和血液学有关的疾病，例如在不对包括给予批准药物的激酶抑制治疗做出反应的患者中的骨髓增生性疾病。
• INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
  申请人：University Health Network

  公开号：US20140371202A1

  公开（公告）日：2014-12-18

  The present teaching provide indazole compounds represented by Structural Formulae (I) or (I′) or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

  本教学提供由结构式（I）或（I'）所代表的吲唑化合物或其药学上可接受的盐。还描述了制备药物组合物和使用方法，作为蛋白激酶抑制剂，例如TTK蛋白激酶，极化样激酶4（PLK4）和极化激酶，对乳腺癌细胞，结肠癌细胞和卵巢癌细胞具有抗癌活性。
• KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
  申请人：UNIVERISTY HEALTH NETWORKS

  公开号：US20140051679A1

  公开（公告）日：2014-02-20

  The present teachings provide a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

  本文提供了一种由结构式（I）表示的化合物，或其药学上可接受的盐。还描述了这些药物组合物的制备方法和使用方法。
• SGLTS/DPP4 INHIBITOR AND APPLICATION THEREOF
  申请人：Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd.

  公开号：EP4005568A1

  公开（公告）日：2022-06-01

  A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable salts thereof are specifically involved.

  一类化合物作为SGLT1/SGLT2/DPP4三重抑制剂，并应用于制备作为SGLT1/SGLT2/DPP4三重抑制剂的药物。具体涉及公式（I）所代表的化合物、同分异构体和药学上可接受的盐。